Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
17 11 2021
Historique:
received: 14 10 2021
revised: 07 11 2021
accepted: 10 11 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 18 12 2021
Statut: epublish

Résumé

Chimeric-antigen-receptor-T (CAR-T) cells are currently revolutionizing the field of cancer immunotherapy. Therefore, there is an urgent need for CAR-T cell monitoring by clinicians to assess cell expansion and persistence in patients. CAR-T cell manufacturers and researchers need to evaluate transduction efficiency and vector copy number for quality control. Here, CAR expression was analyzed in peripheral blood samples from patients and healthy donors by flow cytometry with four commercially available detection reagents and on the gene level by quantitative polymerase chain reaction (qPCR). Flow cytometric analysis of CAR expression showed higher mean CAR expression values for CD19 CAR detection reagent and the F(ab')2 antibody than Protein L and CD19 Protein. In addition, the CD19 CAR detection reagent showed a significantly lower median background staining of 0.02% (range 0.007-0.06%) when compared to the F(ab')2 antibody, CD19 protein and Protein L with 0.80% (range 0.47-1.58%), 0.65% (range 0.25-1.35%) and 0.73% (range 0.44-1.23%). Furthermore, flow cytometry-based CAR-T cell frequencies by CD19 CAR detection reagent showed a good correlation with qPCR results. In conclusion, quality control of CAR-T cell products can be performed by FACS and qPCR. For the monitoring of CAR-T cell frequencies by FACS in patients, CAR detection reagents with a low background staining are preferable.

Identifiants

pubmed: 34831430
pii: cells10113208
doi: 10.3390/cells10113208
pmc: PMC8621201
pii:
doi:

Substances chimiques

Antigens, CD19 0
Indicators and Reagents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Center for Tumor Diseases
ID : G845

Références

Mol Cancer. 2019 Aug 20;18(1):125
pubmed: 31429760
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Mol Ther. 2017 Sep 6;25(9):2189-2201
pubmed: 28676342
Sci Transl Med. 2017 Nov 22;9(417):
pubmed: 29167392
Sci Transl Med. 2016 Sep 7;8(355):355ra116
pubmed: 27605551
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
Cytometry B Clin Cytom. 2009 Nov;76(6):355-64
pubmed: 19575390
Front Immunol. 2018 Jan 10;8:1956
pubmed: 29375575
Blood. 2010 Nov 18;116(20):4099-102
pubmed: 20668228
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
J Immunol Methods. 1993 Aug 26;164(1):33-40
pubmed: 8360508
Blood. 2011 Nov 3;118(18):4817-28
pubmed: 21849486
Cells. 2020 May 15;9(5):
pubmed: 32429189
Immunol Cell Biol. 2019 Aug;97(7):664-674
pubmed: 31009109
Mol Ther Oncolytics. 2016 Apr 20;3:16011
pubmed: 27626062
Ann Oncol. 2021 Jan;32(1):34-48
pubmed: 33098993
Br J Cancer. 2019 Jan;120(1):26-37
pubmed: 30413825
J Transl Med. 2012 Feb 13;10:29
pubmed: 22330761
Blood Adv. 2020 Dec 22;4(24):6157-6168
pubmed: 33351108
Sci Transl Med. 2015 Sep 2;7(303):303ra139
pubmed: 26333935
Nat Rev Clin Oncol. 2020 Mar;17(3):147-167
pubmed: 31848460
Front Immunol. 2020 Aug 11;11:1770
pubmed: 32849635
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Mol Ther Methods Clin Dev. 2020 Feb 20;17:448-454
pubmed: 32201711
Cancers (Basel). 2020 Sep 30;12(10):
pubmed: 33007926

Auteurs

Nicola Schanda (N)

Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Tim Sauer (T)

Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Alexander Kunz (A)

Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Angela Hückelhoven-Krauss (A)

Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Brigitte Neuber (B)

Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Lei Wang (L)

Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Mandy Hinkelbein (M)

Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

David Sedloev (D)

Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Bailin He (B)

Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Maria-Luisa Schubert (ML)

Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Carsten Müller-Tidow (C)

Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Michael Schmitt (M)

Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Anita Schmitt (A)

Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH